Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report

Figure 2 Circulating tumor cells and dynamic change of serum total prostate-specific antigen level. A: Dynamic change of serum total prostate-specific antigen level during the overall treatment with various therapeutic approaches (androgen-deprivation therapy; docetaxel; abiraterone; clinical trial; the PARP inhibitor, olaparib); B: The epithelial-circulating tumor cell (E-CTC), mesenchymal-CTC (M-CTC) and epithelial mesenchymal transition-CTC (EMT-CTC) counts and change before (2017-06-13) and after (2018-06-19) abiraterone treatment. Expression of AR-V7 mRNA was detected in these CTCs; C: Representative graphs displaying the E-CTC, M-CTC and EMT-CTC. Red signal: Probe mixture for detection of mRNA of EpCAM, CK8, CK18, and CK19; Green signal: Probe mixture for detection of mRNA of vimentin and Twist. CTC: Circulating tumor cell.